Advertisement
Amazon
Amazon

The Scientist

» IPO

Most Recent

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Biotech IPOs Surge

Biotech IPOs Surge

By | August 23, 2013

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

0 Comments

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

Advertisement

Popular Now

  1. The Zombie Literature
    Features The Zombie Literature

    Retractions are on the rise. But reams of flawed research papers persist in the scientific literature. Is it time to change the way papers are published?

  2. First Data from Anti-Aging Gene Therapy
  3. Locating Language within the Brain
  4. The Two Faces of Fish Oil
    Notebook The Two Faces of Fish Oil

    The discovery of a tumor-protecting role for a fatty acid found in fish oil has sparked debate about the product’s safety.

Advertisement
SomaLogic
SomaLogic
Advertisement
LabX
LabX
RayBioTech